Sector Experts

Subscribe to
Streetwise Reports

Companies Commented On

  • Anthera Pharmaceuticals Inc.
  • Applied Genetic Technologies Corp.
  • BIND Therapeutics Inc.
  • Can-Fite BioPharma Ltd.
  • Celgene Corp.
  • Celldex Therapeutics Inc.
  • Cerus Corp.
  • CTI BioPharma
  • CytoSorbents Corp.
  • Galapagos NV
  • Incyte Corp.
  • Lion Biotechnologies
  • MEI Pharma Inc.
  • MorphoSys
  • Novavax Inc.
  • Omeros Corp.
  • OncoGenex Pharmaceuticals Inc.
  • OncoSec Medical Inc.
  • Oncothyreon Inc.
  • Paratek Pharmaceuticals Inc.
  • Peregrine Pharmaceuticals Inc.
  • Pharmacyclics Inc.
  • Pluristem Therapeutics Inc.
  • Sunesis Pharmaceuticals Inc.
  • Synta Pharmaceuticals Corp.
  • TG Therapeutics Inc.
  • Threshold Pharmaceuticals Inc.
  • Verastem Inc.

George Zavoico

JonesTrading International Services LLC

Image: George Zavoico

Dr. George Zavoico, senior equity analyst at JonesTrading Institutional Services LLC, has more than 10 years of experience as a life sciences equity analyst writing research on publicly traded equities. His principal focus is on biotechnology, biopharmaceutical, specialty pharmaceutical, and molecular diagnostics companies. Previously, Zavoico was a senior equity research analyst in the healthcare sector at MLV & Co., and an equity analyst at Cantor Fitzgerald and Westport Capital Markets. Prior to becoming an equity analyst, Zavoico established his own consulting company serving the biotech and pharmaceutical industries, providing competitive intelligence and marketing research, due diligence services and guidance in regulatory affairs. Zavoico began his career as a senior research scientist at Bristol-Myers Squibb Co., moving on to management positions at Alexion Pharmaceuticals Inc. and T Cell Sciences Inc. (now Celldex Therapeutics Inc.). Zavoico has a bachelor's degree in biology from St. Lawrence University and a Ph.D. in physiology from the University of Virginia. He held post-doctoral fellowships at the University of Connecticut School of Medicine and Harvard Medical School/Brigham & Women's Hospital. He has published more than 30 papers in peer-reviewed journals and has coauthored four book chapters. He received The Financial Times/Starmine Award two years in a row for being among the top-ranked earnings estimators in the biotechnology sector.




Recent Interviews

A Bull Run Hiccup: 2015 Small-Cap Biotech Watchlist Update (5/13/15) It's been four months since The Life Sciences Report's 2015 Small-Cap Biotech Watchlist was announced at the Biotech Showcase in San Francisco. The year is off to a bumpy start, though the rough ride is not predicated, necessarily, on individual company performance. Read on for highlights of the Watchlist's Q1/15 performance.

Watchlist Analysts Forecast Continued Blue Sky for Biotech Industry (1/29/15) For the last two years the biotech sector has experienced market-beating gains, even taking into account the industry-wide hiccup in early 2014. Can this trend continue? The five analysts who selected names for The Life Sciences Report's 2015 Small-Cap Biotech Watchlist spend their days considering this question; it comes into play with every recommendation they make. The topic came up in various contexts during the Watchlist panel at the 2015 Biotech Showcase: Here are four factors investors should consider as they move into 2015.

The Small-Cap Biotech Watchlist 2015 Unwrapped: Who Are These Guys? And Why Are They Here? (1/27/15) At the Biotech Showcase 2015 in San Francisco, five biotech analysts examined the burgeoning small-cap life sciences marketplace and found every reason to believe its good health would continue into 2015 and beyond. The experts also sent investors who attended the panel discussion of The Life Sciences Report's 2015 Small-Cap Biotech Watchlist home with a bundle of robust investment opportunities, including a few new names. Read on to see which companies made the list, and why.

Recent Quotes

"We are raising our price target for OMER." (2/18/15) Omeros Corp. - George Zavoico, MLV & Co More >

"THLD's Phase 3 soft tissue sarcoma trial is likely to play out with topline results by Q3/15 or Q4/15." (1/27/15) Threshold Pharmaceuticals Inc. - The Life Sciences Report Interview with George Zavoico More >

"Our view [is] that THLD's TH-302 is a platform in a single drug." (12/19/14) Threshold Pharmaceuticals Inc. - George Zavoico, MLV & Co More >

"GLPG is notable and underappreciated." (11/12/14) Galapagos NV - The Life Sciences Report Interview with George Zavoico More >

"Positive data in the pancreatic or the sarcoma studies could take THLD shares to my target." (11/12/14) Threshold Pharmaceuticals Inc. - The Life Sciences Report Interview with George Zavoico More >

"We see a pretty healthy revenue stream coming from OMER's Omidria." (11/12/14) Omeros Corp. - The Life Sciences Report Interview with George Zavoico More >

"We believe that OMER will become profitable in 2016." (11/6/14) Omeros Corp. - The Life Sciences Report Biotech Watchlist Update with George Zavoico More >

"We continue to believe OMER's OMS824 to be safe and expect the Phase 2 trial to resume." (10/22/14) Omeros Corp. - George Zavoico, MLV & Co More >

more comments

"We think THLD could become profitable in 2016 based on revenue from sales of TH-302." (10/13/14) Threshold Pharmaceuticals Inc. - George Zavoico, MLV & Co More >

"I believe THLD's drug works, and momentum for the company is building." (3/6/14) Threshold Pharmaceuticals Inc. - The Life Sciences Report Interview with George Zavoico More >

"PSTI's ability to vary the cell phenotype for a specific therapy is unique in the regenerative medicine space." (3/6/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with George Zavoico More >

"Behind Omidria, OMER has a robust pipeline that has advanced into a number of phase 1 and phase 2 trials." (3/6/14) Omeros Corp. - The Life Sciences Report Interview with George Zavoico More >

"PSTI announced positive results of a preclinical study of its PLX cells." (11/5/13) Pluristem Therapeutics Inc. - George Zavoico, MLV & Co More >

"We view the expansion of PSTI's trial into Israel as an effective strategy to accelerate patient enrollment." (10/2/13) Pluristem Therapeutics Inc. - George Zavoico, MLV & Co More >

"PSTI's preclinical study provides additional evidence of efficacy." (10/1/13) Pluristem Therapeutics Inc. - George Zavoico, MLV & Co More >

(8/15/13) Threshold Pharmaceuticals Inc. - The Life Sciences Report Interview with George Zavoico More >

fewer comments


Due to permission requirements, not all quotes are shown.